At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 03-13 16:00:00 EDT
0.9735
+0.1645
+20.33%
盘后1.01
+0.0365+3.75%
19:59 EDT
High1.10Low0.8425Vol13.55M
Open0.8510D1 Closing0.8090Amplitude31.83%
Mkt Cap20.77MTradable Cap16.31MTotal Shares21.33M
T/O13.54MT/O Rate80.87%Tradable Shares16.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron Inc. Files Initial Beneficial Ownership Statement for CEO Stephen H. Willard
Reuters  ·  03-14 08:59
Longeveron Inc. Files Initial Beneficial Ownership Statement for CEO Stephen H. Willard
Longeveron Inc. to report full-year 2025 financial results and host conference call
Reuters  ·  03-12 21:05
Longeveron Inc. to report full-year 2025 financial results and host conference call
Longeveron closes USD 15 million private placement of shares
Reuters  ·  03-12
Longeveron closes USD 15 million private placement of shares
Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million
Dow Jones  ·  03-12
Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million
3 Penny Stocks to Watch Now, 3/11/26
TIPRANKS  ·  03-11
3 Penny Stocks to Watch Now, 3/11/26
Longeveron prices 6.01M shares at 52c in private placement
TIPRANKS  ·  03-10
Longeveron prices 6.01M shares at 52c in private placement
Press Release: Longeveron Announces Private Placement of up to $30 Million
Dow Jones  ·  03-10
Press Release: Longeveron Announces Private Placement of up to $30 Million
Longeveron reports Phase 2b trial results showing laromestrocel improves age-related frailty in Cell Stem Cell
Reuters  ·  02-26
Longeveron reports Phase 2b trial results showing laromestrocel improves age-related frailty in Cell Stem Cell
Longeveron® Results of Phase 2B Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients With Age-Related Frailty Published in Cell Stem Cell
THOMSON REUTERS  ·  02-26
Longeveron® Results of Phase 2B Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients With Age-Related Frailty Published in Cell Stem Cell
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives
TIPRANKS  ·  02-14
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives
Longeveron Appoints Stephen Willard as CEO
MT Newswires Live  ·  02-14
Longeveron Appoints Stephen Willard as CEO
Longeveron Names Stephen H. Willard as Chief Executive Officer
Reuters  ·  02-14
Longeveron Names Stephen H. Willard as Chief Executive Officer
Longeveron Inc - Than Powell Steps Down as Interim CEO
THOMSON REUTERS  ·  02-14
Longeveron Inc - Than Powell Steps Down as Interim CEO
Longeveron Inc: Phase 2B Clinical Trial in Hypoplastic Left Heart Syndrome Anticipated in Q3 of 2026
THOMSON REUTERS  ·  02-14
Longeveron Inc: Phase 2B Clinical Trial in Hypoplastic Left Heart Syndrome Anticipated in Q3 of 2026
Press Release: Longeveron(R) Appoints Stephen H. Willard as Chief Executive Officer
Dow Jones  ·  02-14
Press Release: Longeveron(R) Appoints Stephen H. Willard as Chief Executive Officer
Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage
TIPRANKS  ·  02-05
Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
GlobeNewswire  ·  02-05
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Longeveron granted Japan patent for potency assay methods for MSCs
TIPRANKS  ·  01-29
Longeveron granted Japan patent for potency assay methods for MSCs
Longeveron Granted Japan Patent for Potency Assay Methods for Human Mesenchymal Stem Cells
Reuters  ·  01-29
Longeveron Granted Japan Patent for Potency Assay Methods for Human Mesenchymal Stem Cells
Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout
TIPRANKS  ·  01-26
Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--